22-09-2022 дата публикации
Номер: US20220298254A1
CD47 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the CD47 antigen-binding molecules. 139.-. (canceled)40. An antigen-binding molecule which binds to CD47 , comprising: HC-CDR1 having the amino acid sequence of SEQ ID NO:169', 'HC-CDR2 having the amino acid sequence of SEQ ID NO:170', 'HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and, '(i) a heavy chain variable (VH) region incorporating the following CDRs LC-CDR1 having the amino acid sequence of SEQ ID NO:171', 'LC-CDR2 having the amino acid sequence of SEQ ID NO:172', 'LC-CDR3 having the amino acid sequence of SEQ ID NO:173., '(ii) a light chain variable (VL) region incorporating the following CDRs42. The antigen-binding molecule according to claim 40 , wherein the antigen-binding molecule comprises:a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132, 23, 39, 178, 127, 129, 130 or 131; anda VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128, 31, 44, 179, 133, 134, 135 or 136.44. The antigen-binding molecule according to claim 40 , wherein the antigen-binding molecule inhibits interaction between CD47 and SIRPα.45. The antigen-binding molecule according to claim 40 , wherein the antigen-binding molecule is a multispecific antigen-binding molecule claim 40 , and further comprises an antigen-binding domain specific for a target antigen other than CD47.46. A nucleic acid claim 40 , or a plurality of nucleic acids claim 40 , encoding an antigen-binding molecule which binds to CD47 claim 40 , comprising: HC-CDR1 having the amino acid sequence of SEQ ID NO:169', 'HC-CDR2 having the amino acid sequence of SEQ ID NO:170', 'HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and, '(i) a heavy chain variable (VH) region incorporating the following CDRs LC- ...
Подробнее